Phospho-Synuclein alpha (Tyr133) Antibody - #AF3286
产品: | 磷酸化 Synuclein alpha (Tyr133) 抗体 |
货号: | AF3286 |
描述: | Rabbit polyclonal antibody to Phospho-Synuclein alpha (Tyr133) |
应用: | WB IF/ICC |
反应: | Human, Mouse, Rat |
预测: | Pig, Bovine, Horse, Rabbit, Dog, Chicken |
分子量: | 18kDa; 14kD(Calculated). |
蛋白号: | P37840 |
RRID: | AB_2834707 |
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF3286, RRID:AB_2834707.
展开/折叠
Alpha synuclein; Alpha-synuclein; Alpha-synuclein, isoform NACP140; alphaSYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid; Non A4 component of amyloid precursor; Non-A beta component of AD amyloid; Non-A-beta component of alzheimers disease amyloid , precursor of; Non-A4 component of amyloid precursor; Non-A4 component of amyloid, precursor of; OTTHUMP00000218549; OTTHUMP00000218551; OTTHUMP00000218552; OTTHUMP00000218553; OTTHUMP00000218554; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease (autosomal dominant, Lewy body) 4; Parkinson disease familial 1; SNCA; Snca synuclein, alpha (non A4 component of amyloid precursor); SYN; Synuclein alpha; Synuclein alpha 140; Synuclein, alpha (non A4 component of amyloid precursor); SYUA_HUMAN;
抗原和靶标
Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.
- P37840 SYUA_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - P37840 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
Ubiquitination | Uniprot | ||
M1 | Acetylation | Uniprot | |
K6 | Sumoylation | Uniprot | |
K10 | Sumoylation | Uniprot | |
K12 | Sumoylation | Uniprot | |
K12 | Ubiquitination | Uniprot | |
K21 | Acetylation | Uniprot | |
K21 | Sumoylation | Uniprot | |
K21 | Ubiquitination | Uniprot | |
K23 | Sumoylation | Uniprot | |
K23 | Ubiquitination | Uniprot | |
K34 | Sumoylation | Uniprot | |
Y39 | Phosphorylation | Uniprot | |
S42 | Phosphorylation | Uniprot | |
K45 | Sumoylation | Uniprot | |
T54 | O-Glycosylation | Uniprot | |
K58 | Acetylation | Uniprot | |
K60 | Sumoylation | Uniprot | |
K80 | Sumoylation | Uniprot | |
S87 | O-Glycosylation | Uniprot | |
S87 | Phosphorylation | P48729 (CSNK1A1) , P68400 (CSNK2A1) , Q13627 (DYRK1A) | Uniprot |
K96 | Acetylation | Uniprot | |
K96 | Sumoylation | Uniprot | |
K102 | Sumoylation | Uniprot | |
Y125 | Phosphorylation | P06241 (FYN) , Q14289 (PTK2B) , P12931 (SRC) , P43405 (SYK) | Uniprot |
S129 | Phosphorylation | P68400 (CSNK2A1) , P49841 (GSK3B) , P53350 (PLK1) , Q5S007 (LRRK2) , P25098 (GRK2) , P34947 (GRK5) , P48729 (CSNK1A1) , Q9UQM7 (CAMK2A) , P43250 (GRK6) , Q9H4B4 (PLK3) , Q9NYY3 (PLK2) | Uniprot |
Y133 | Phosphorylation | P43405 (SYK) | Uniprot |
Y136 | Phosphorylation | P43405 (SYK) | Uniprot |
研究背景
Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity.
Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
Cytoplasm. Membrane. Nucleus. Cell junction>Synapse. Secreted.
Note: Membrane-bound in dopaminergic neurons.
Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.
Soluble monomer. Homotetramer. A dynamic intracellular population of tetramers and monomers coexists normally and the tetramer plays an essential role in maintaining homeostasis. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones. Interacts (via N-terminus) with synphilin-1/SNCAIP; this interaction promotes formation of SNCA inclusions in the cytoplasm. Interacts with CALM1. Interacts with STXBP1; this interaction controls SNCA self-replicating aggregation. Interacts with SNARE components VAMP2 and SNAP25; these interactions allows SNARE complex assembly and integrity. Interacts with RPH3A and RAB3A. Interacts with SERF1A; this interaction promotes the aggregation of SNCA.
The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
Belongs to the synuclein family.
研究领域
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
· Human Diseases > Neurodegenerative diseases > Parkinson's disease.
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.